Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Zogenix (ZGNX) Expects Phase 3 Study 1501 data for ZX008 in Dravet Syndrome in Late 2016

Source Link:: http://www.sec.gov/Archives/edgar/data/1375151/000119312515402506/d103220d8k.htm

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

ZGNX

66%

GWPH

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details A quote from a Dravet expert Slingshot Insights interviewed: "As a patient population, I think they actually should be very easy to define. I think the bigger problem is that a lot of patients who may have Dravet syndrome and may be candidates to be included in this are probably not being picked, though. I think that this is a condition where we are just scratching the surface of just how common it is. I think that you'll find that the true incidence will actually increase as genetic testing becomes more widely available and as people begin to understand that this particular epilepsy syndrome has a very specific epilepsy treatment that should be considered." Full interview in the source.

http://slingshotinsi...

Clinical Data A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome

https://clinicaltria...

Management Comment "Top line safety and efficacy results from studying 1501, the North America Phase 3 safety and efficacy trial which we are targeting for the end of 2016. With results for study 1502 approximately a quarter later."

http://seekingalpha....

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Dec 05, 2016

Occurred Source:

http://ir.zogenix.com/phoenix.zhtml?c=220862&p=irol-newsArticle&ID=2227454

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Dravet Syndrome, Zx008, Fenfluramine, Brabafen, Epidiolex